期刊文献+

子宫内膜癌患者PTEN的表达及其临床意义探讨 被引量:1

Discussion of the expression and significance of PTEN in the patients with endometrial cancer
原文传递
导出
摘要 目的:研究抑癌基因PTEN在子宫内膜腺癌组织中的表达及其与预后的关系。方法:采用免疫组化SP法检测103例子宫内膜腺癌病理标本PTEN的表达,并对其中54例患者进行5年随访,对PTEN表达情况与生存率进行相关性分析。结果:①子宫内膜腺癌患者PTEN阳性表达率明显高于健康对照组(χ2=83.96,P<0.001)。②子宫内膜腺癌组织分级G3级、临床分期Ⅲ-Ⅳ期、浸润超过1/2肌层厚度及有淋巴结转移者PTEN阳性表达明显降低。③PTEN阳性率与子宫内膜癌术后5年存活率有关(χ2=7.64,r=0.3521,P<0.01),PTEN高表达者,术后5年存活率也越高。结论:子宫内膜癌患者存在PTEN表达下调,PTEN表达与子宫内膜癌临床病理分级、分期、癌细胞浸润、转移及预后有关;子宫内膜组织PTEN检测对诊断子宫内膜癌并判定其恶性程度和预后具有重要意义。 Objective: To study the expression of tumor suppressor gene -PTEN in endometrial adenocarcinoma and its relationship with the prognosis. Methods : Immunohistochemical SP method was used to detect the expression of PTEN in 103 specimens of endometrial adenocarcinoma, and 54 patients were followed up for five years, the con'elation between the expression of PTEN and survival rate was analyzed. Results: The positive expression rate of PTEN in endometrial adenocarcinoma group was significantly higher than that in health control group (X^2 = 83.96, P 〈 0. 001 ) . In endometrial adenoeareinoma group, the positive expression rate of PTEN among the patients with G3 grade, stage Ⅲ- Ⅳ, the depth of invasion more than 1/2 of myometrium, and lymph node metastasis decreased significantly. There was correlation between the positive rate of PTEN and five - year survival rate (X2 =-7.64, Y = 0. 3521, P 〈 0. 01 ), the higher the positive rate of PTEN was, the higher five - year survival rate was. Conclusion: Down - regulation of PTEN exists in the patients with endometrial adenocarcinoma, PTEN expression is correlated with clinicopathological grades, clinical stages, invasion, metastasis, and prognosis of endo- metrial adenocarcinoma; PTEN detection plays an important role in diagnosing endometrial adenocarcinoma and determining malignant degree and prognosis.
作者 范真
出处 《中国妇幼保健》 CAS 北大核心 2012年第16期2511-2513,共3页 Maternal and Child Health Care of China
关键词 子宫内膜腺癌 抑癌基因 PTEN Endometrial adenocarcinoma Tumor suppressor gene PTEN
  • 相关文献

参考文献4

二级参考文献64

  • 1[1]Li J,Yen C,Liaw D,et al. PTEN,a putative protein tyrosine phosphatese gene mutated in human brain,breast,and prostate cancer [J]. Science,1997, 275:1943- 1947.
  • 2[2]Constantine A,Monteagado O,Merino HJ,et al. Immunohisto- chemical detection of P- glycoprotein in endometrial adenocarcinoma [J]. Am J Pathol,1991,138:799- 806.
  • 3[3]Tashiro H,Blazes MS,Wu R,et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies [J]. Cancer Res,1997, 57:3935- 3940.
  • 4[4]Kinzler KW,Vogelstein B. Cancer- susceptibility genes. Gatekeepers and caretakers [J]. Nature,1997, 386:761- 763.
  • 5[5]Teng DH,Hu R,Lin H,et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines [J]. Cancer Res,1997,57:5221- 5225.
  • 6[6]Mutter GL,Lin MC,Fitzgerald JT,et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers [J]. J Natl Cancer Inst,2000, 92:924- 931.
  • 7[7]Whang YE,Wu X,Suzuki H,et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression [J]. Proc Natl Acad Sci USA,1998, 95:5246- 5250.
  • 8[1]Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH,Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R,Swedlund B, Teng DH, Tavtigian SV. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15:356-362
  • 9[2]Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J,Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC,Ittmarn M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN,a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-1947
  • 10[3]Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57:2124-2129

共引文献173

同被引文献17

  • 1Danescu A, Herrero Gonzalez S, Di Cristofano A, et al. Three - dimen- sional nuclear telomere architecture changes during endometrial carcino- ma development[ J]. Genes Chromosomes Cancer, 2013,52 ( 8 ) :716 -732.
  • 2Monte NM, Webster KA, Neuberg D, et al. Joint loss of PAX2 and PTEN expression in endometrialprecancers and cancer[ J]. Cancer Res, 2010,70 ( 15 ) :6225 - 632.
  • 3Diordievic B, Hennessy BT, Li J, et al. Clinical assessment of PTEN immunohistochemistry outperforms genese- quencing [ J ]. Mod Pathol, 2012,25 (5) :699 - 708.
  • 4Wemer HM, Berg A, Wik A, et al. ARID1A loss is prevalent in endo- metrial hyperplasia with atypia and low - grade endometrioid carcinomas [J]. Mod Pathol, 2013,26(3) :428 -434.
  • 5Wild PJ, Ikenberg K, Fuchs TJ, et al. p53 suppresses type II endome- trial carcinomas in mice and governs endometrial tumour aggressiveness in humans[J]. EMBO Mol Med, 2012,4(8) : 808 -824.
  • 6Saito F, Tashiro H, To Y, et al. Mutual contribution of Pten and estro- gen to endometrial carcinogenesis in a PtenloxP/loxP mouse model[ J]. Int J Gynecol Cancer, 2011,21 (8) : 1343 - 1349.
  • 7Garg K, Broaddus RR, Soslow RA, et al. Pathologic scoring of PTEN immunohistochemistry in endometfial carcinoma is highly reproducible [J]. Int J Gynecol Pathol, 2012,31(1) :48 -56.
  • 8Kwon JS, Lenehan J, Carey M, et al. Prolonged survival among women with BRCA germline mutations and advanced endometrial cancer: a case series[ J]. Int J Gynecol Cancer, 2008,18 (3) :546 - 549.
  • 9Simmons CD, Pabona JM, Heard ME, et al. Kriippel - like factor 9 loss- of- expression in humanendometrial carcinoma links altered ex- pression of growth - regulatory genes with aberrant proliferative responseto estrogen[ J]. Biol Reprod, 2011,85 ( 2 ) :378 - 385.
  • 10赵岩,刘岿然,张淑兰.子宫内膜癌中抑癌基因PTEN突变与微卫星不稳定性的相关性分析[J].中国医科大学学报,2010,39(2):119-122. 被引量:3

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部